Inhaled Corticosteroid Daily Dosages				
Medication	Age	Low	Medium	High
Beclomethasone (Qvar® HFA)	Adult	80-240	240-480	>480
• MDI 40, 80 mcg/puff, divided BID	5-11	80-160	160-320	>320
Budesonide (Pulmicort® Flexhaler)	Adult	200-540	540-1080	>1080
• DPI 90, 180 mcg/inh, divided BID	5-11	180-360	360-720	>720
Budesonide (Pulmicort® Respules)	5-11	0.5	1.0	2.0
• Neb soln 0.25, 0.5, 1 mg, divided BID	0-4	0.25-0.5	0.5-1.0	>1.0
Ciclesonide (Alvesco® HFA)	Adult	160-320	320-640	>640
• MDI 80, 160 mcg/puff, divided BID				
Fluticasone (Flovent® Diskus)	Adult	100-300	300-600	>600
• DPI 50, 100, 250 mcg/puff, divided BID	4-11	100-200	200-400	>400
Fluticasone (Flovent® HFA)	Adult	88-264	264-440	>440
• MDI 44, 110, 220 mcg/puff, divided BID	0-11	88-176	176-352	>352
Mometasone (Asmanex® TwistHaler)	Adult	220	440	>440
• DPI 110, 220 mcg/puff, daily PM or BID	5-11	110	220-440	>440

Inhaled Corticosteroid Daily Dosages				
Medication	Age	Low	Medium	High
Beclomethasone (Qvar® HFA)	Adult	80-240	240-480	>480
• MDI 40, 80 mcg/puff, divided BID	5-11	80-160	160-320	>320
Budesonide (Pulmicort® Flexhaler)	Adult	200-540	540-1080	>1080
• DPI 90, 180 mcg/inh, divided BID	5-11	180-360	360-720	>720
Budesonide (Pulmicort® Respules)	5-11	0.5	1.0	2.0
• Neb soln 0.25, 0.5, 1 mg, divided BID	0-4	0.25-0.5	0.5-1.0	>1.0
Ciclesonide (Alvesco® HFA)	Adult	160-320	320-640	>640
• MDI 80, 160 mcg/puff, divided BID				
Fluticasone (Flovent® Diskus)	Adult	100-300	300-600	>600
• DPI 50, 100, 250 mcg/puff, divided BID	4-11	100-200	200-400	>400
Fluticasone (Flovent® HFA)	Adult	88-264	264-440	>440
• MDI 44, 110, 220 mcg/puff, divided BID	0-11	88-176	176-352	>352
Mometasone (Asmanex® TwistHaler)	Adult	220	440	>440
• DPI 110, 220 mcg/puff, daily PM or BID	5-11	110	220-440	>440

Asthma Severity Classification*

	Day Sx	Night Sx	FEV_1	SABA use
Severe Persistent	Continual	≥1/week	<60%	2-3x/day
Moderate Persistent	Daily	≥5/month	60-80%	Daily
Mild Persistent	3-6/week	3-4/month	>80%	≥2/week
Intermittent	≤2/week	≤2/month	>80%	≤2/week

* Patients should be assigned to the most severe category in which *any* feature occurs.

Exacerbations requiring oral steroids

Intermittent: all ages 0-1/year	Persistent: consider severity and interval since last episode Age 0-4: >2 in 6 months All ages: >2/year

Asthma Severity Classification*

	Day Sx	Night Sx	FEV_1	SABA use
Severe Persistent	Continual	≥1/week	<60%	2-3x/day
Moderate Persistent	Daily	≥5/month	60-80%	Daily
Mild Persistent	3-6/week	3-4/month	>80%	≥2/week
Intermittent	≤2/week	≤2/month	>80%	≤2/week

* Patients should be assigned to the most severe category in which *any* feature occurs.

Exacerbations requiring oral steroids

Intermittent: all ages 0-1/year	Persistent: consider severity and interval since last episode Age 0-4: >2 in 6 months All ages: >2/year

Asthma Severity Classification*

	Day Sx	Night Sx	FEV_1	SABA use
Severe Persistent	Continual	≥1/week	<60%	2-3x/day
Moderate Persistent	Daily	≥5/month	60-80%	Daily
Mild Persistent	3-6/week	3-4/month	>80%	≥2/week
Intermittent	≤2/week	≤2/month	>80%	≤2/week

* Patients should be assigned to the most severe category in which *any* feature occurs.

Exacerbations requiring oral steroids

Intermittent: all ages 0-1/year	Persistent: consider severity and interval since last episode Age 0-4: >2 in 6 months All ages: >2/year

Asthma Severity Classification*

	Day Sx	Night Sx	FEV_1	SABA use
Severe Persistent	Continual	≥1/week	<60%	2-3x/day
Moderate Persistent	Daily	≥5/month	60-80%	Daily
Mild Persistent	3-6/week	3-4/month	>80%	≥2/week
Intermittent	≤2/week	≤2/month	>80%	≤2/week

* Patients should be assigned to the most severe category in which *any* feature occurs.

Exacerbations requiring oral steroids

Intermittent: all ages 0-1/year	Persistent: consider severity and interval since last episode Age 0-4: >2 in 6 months All ages: >2/year

Asthma Severity Classification*

	Day Sx	Night Sx	FEV_1	SABA use
Severe Persistent	Continual	≥1/week	<60%	2-3x/day
Moderate Persistent	Daily	≥5/month	60-80%	Daily
Mild Persistent	3-6/week	3-4/month	>80%	≥2/week
Intermittent	≤2/week	≤2/month	>80%	≤2/week

* Patients should be assigned to the most severe category in which *any* feature occurs.

Exacerbations requiring oral steroids

Intermittent: all ages 0-1/year	Persistent: consider severity and interval since last episode Age 0-4: >2 in 6 months All ages: >2/year

Asthma Severity Classification*

	Day Sx	Night Sx	FEV_1	SABA use
Severe Persistent	Continual	≥1/week	<60%	2-3x/day
Moderate Persistent	Daily	≥5/month	60-80%	Daily
Mild Persistent	3-6/week	3-4/month	>80%	≥2/week
Intermittent	≤2/week	≤2/month	>80%	≤2/week

* Patients should be assigned to the most severe category in which *any* feature occurs.

Exacerbations requiring oral steroids

Intermittent: all ages 0-1/year	Persistent: consider severity and interval since last episode Age 0-4: >2 in 6 months All ages: >2/year

Asthma Severity Classification*

	Day Sx	Night Sx	FEV_1	SABA use
Severe Persistent	Continual	≥1/week	<60%	2-3x/day
Moderate Persistent	Daily	≥5/month	60-80%	Daily
Mild Persistent	3-6/week	3-4/month	>80%	≥2/week
Intermittent	≤2/week	≤2/month	>80%	≤2/week

* Patients should be assigned to the most severe category in which *any* feature occurs.

Exacerbations requiring oral steroids

Intermittent: all ages 0-1/year	Persistent: consider severity and interval since last episode Age 0-4: >2 in 6 months All ages: >2/year

Asthma Severity Classification*

	Day Sx	Night Sx	FEV_1	SABA use
Severe Persistent	Continual	≥1/week	<60%	2-3x/day
Moderate Persistent	Daily	≥5/month	60-80%	Daily
Mild Persistent	3-6/week	3-4/month	>80%	≥2/week
Intermittent	≤2/week	≤2/month	>80%	≤2/week

* Patients should be assigned to the most severe category in which *any* feature occurs.

Exacerbations requiring oral steroids

Intermittent: all ages 0-1/year	Persistent: consider severity and interval since last episode Age 0-4: >2 in 6 months All ages: >2/year

Asthma Severity Classification*

	Day Sx	Night Sx	FEV_1	SABA use
Severe Persistent	Continual	≥1/week	<60%	2-3x/day
Moderate Persistent	Daily	≥5/month	60-80%	Daily
Mild Persistent	3-6/week	3-4/month	>80%	≥2/week
Intermittent	≤2/week	≤2/month	>80%	≤2/week

* Patients should be assigned to the most severe category in which *any* feature occurs.

Exacerbations requiring oral steroids

Intermittent: all ages 0-1/year	Persistent: consider severity and interval since last episode Age 0-4: >2 in 6 months All ages: >2/year

Asthma Severity Classification*

	Day Sx	Night Sx	FEV_1	SABA use
Severe Persistent	Continual	≥1/week	<60%	2-3x/day
Moderate Persistent	Daily	≥5/month	60-80%	Daily
Mild Persistent	3-6/week	3-4/month	>80%	≥2/week
Intermittent	≤2/week	≤2/month	>80%	≤2/week

* Patients should be assigned to the most severe category in which *any* feature occurs.

Exacerbations requiring oral steroids

Intermittent: all ages 0-1/year	Persistent: consider severity and interval since last episode Age 0-4: >2 in 6 months All ages: >2/year

Asthma Severity Classification*

	Day Sx	Night Sx	FEV_1	SABA use
Severe Persistent	Continual	≥1/week	<60%	2-3x/day
Moderate Persistent	Daily	≥5/month	60-80%	Daily
Mild Persistent	3-6/week	3-4/month	>80%	≥2/week
Intermittent	≤2/week	≤2/month	>80%	≤2/week

* Patients should be assigned to the most severe category in which *any* feature occurs.

Exacerbations requiring oral steroids

Intermittent: all ages 0-1/year	Persistent: consider severity and interval since last episode Age 0-4: >2 in 6 months All ages: >2/year